As of 2025-07-04, the Intrinsic Value of Carl Zeiss Meditec AG (AFX.DE) is 31.22 EUR. This AFX.DE valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 53.85 EUR, the upside of Carl Zeiss Meditec AG is -42.00%.
The range of the Intrinsic Value is 18.65 - 74.16 EUR
Based on its market price of 53.85 EUR and our intrinsic valuation, Carl Zeiss Meditec AG (AFX.DE) is overvalued by 42.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 18.65 - 74.16 | 31.22 | -42.0% |
| DCF (Growth 10y) | 21.32 - 76.12 | 33.85 | -37.1% |
| DCF (EBITDA 5y) | 38.28 - 57.03 | 46.90 | -12.9% |
| DCF (EBITDA 10y) | 41.54 - 66.99 | 52.83 | -1.9% |
| Fair Value | 18.98 - 18.98 | 18.98 | -64.76% |
| P/E | 50.47 - 58.27 | 54.09 | 0.4% |
| EV/EBITDA | 40.08 - 55.02 | 49.97 | -7.2% |
| EPV | 20.81 - 32.89 | 26.85 | -50.1% |
| DDM - Stable | 17.13 - 69.95 | 43.54 | -19.1% |
| DDM - Multi | 27.83 - 86.12 | 41.81 | -22.4% |
| Market Cap (mil) | 4,816.34 |
| Beta | 1.76 |
| Outstanding shares (mil) | 89.44 |
| Enterprise Value (mil) | 5,384.62 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.69% |
| Cost of Debt | 4.25% |
| WACC | 7.23% |